Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Insulin9623 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A05325 | 33302598 | Int J Mol Sci | Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice. | 2020 | Details |
| A05326 | 33302316 | Horm Metab Res | Acute Elevated Resistin Exacerbates Mitochondrial Damage and Aggravates Liver Steatosis Through AMPK/PGC-1α Signaling Pathway in Male NAFLD Mice. | 2020 | Details |
| A05332 | 33299856 | Biomed Res Int | GCN2 Deficiency Enhances Protective Effects of Exercise on Hepatic Steatosis. | 2020 | Details |
| A05338 | 33297922 | CNS Neurol Disord Drug Targets | Liver-Brain Axis in Sporadic Alzheimer's Disease: Role of Ten Signature Genes in a Mouse Model. | 2021 | Details |
| A05340 | 33296704 | Diabetes Metab | NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. | 2020 | Details |
| A05342 | 33294831 | JHEP Rep | Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease. | 2020 | Details |
| A05345 | 33293347 | Diabetes Care | Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05348 | 33291552 | Children (Basel) | Glutamate-Serine-Glycine Index: A Novel Potential Biomarker in Pediatric Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A05353 | 33289147 | J Food Biochem | A high-fructose diet in rats induces systemic iron deficiency and hepatic iron overload by an inflammation mechanism. | 2020 | Details |
| A05356 | 33284184 | Am J Gastroenterol | Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. | 2021 | Details |
| A05361 | 33282899 | Front Nutr | Corrigendum: PTEN: A Thrifty Gene That Causes Disease in Times of Plenty? | 2020 | Details |
| A05372 | 33279947 | Eur J Clin Nutr | Lipid and saturated fatty acids intake and cardiovascular risk factors of obese children and adolescents. | 2020 | Details |
| A05374 | 33278735 | Curr Opin Pharmacol | The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. | 2020 | Details |
| A05380 | 33276146 | Mol Metab | Mitochondrial oxidative function in NAFLD: Friend or foe? | 2020 | Details |
| A05385 | 33275239 | Eur Rev Med Pharmacol Sci | The relationship between endoplasmic reticulum stress and liver function, insulin resistance and vascular endothelial function in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A05386 | 33275161 | Diabetologia | The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels. | 2020 | Details |
| A05391 | 33273527 | Sci Rep | Deletion of the nuclear receptor RORα in macrophages does not modify the development of obesity, insulin resistance and NASH. | 2020 | Details |
| A05392 | 33272889 | Clin Res Hepatol Gastroenterol | Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis. | 2020 | Details |
| A05395 | 33271878 | Cells | Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using "Good-Fit" Genome-Editing Tools. | 2020 | Details |
| A05397 | 33271332 | Mol Metab | Hepatocyte-specific PKCβ deficiency protects against high-fat diet-induced nonalcoholic hepatic steatosis. | 2020 | Details |
| A05399 | 33270924 | J Bone Miner Res | Osteocalcin and Non-Alcoholic Fatty Liver Disease: Lessons From Two Population-Based Cohorts and Animal Models. | 2020 | Details |
| A05407 | 33269017 | J Med Biochem | Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. | 2020 | Details |
| A05412 | 33268673 | Biomed Res | Plasma lipoprotein profile from nonalcoholic steatohepatitis model rats. | 2020 | Details |
| A05419 | 33266488 | Int J Mol Sci | Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. | 2020 | Details |
| A05428 | 33260451 | Int J Mol Sci | Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. | 2020 | Details |
| A05430 | 33259845 | J Hepatol | Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. | 2020 | Details |
| A05434 | 33257903 | Int J Endocrinol Metab | Effects of Vitamin D Supplementation in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2020 | Details |
| A05438 | 33257471 | Gut | Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance. | 2020 | Details |
| A05443 | 33255404 | Nutrients | POCU1b, the n-Butanol Soluble Fraction of Polygoni Cuspidati Rhizoma et Radix, Attenuates Obesity, Non-Alcoholic Fatty Liver, and Insulin Resistance via Inhibitions of Pancreatic Lipase, cAMP-Dependent PDE Activity, AMPK Activation, and SOCS-3 Suppression. | 2020 | Details |
| A05450 | 33252713 | Protein Cell | Targeting the alternative bile acid synthetic pathway for metabolic diseases. | 2020 | Details |
| A05457 | 33249742 | Mol Nutr Food Res | Catechin-Rich Green Tea Extract and the Loss-of-TLR4 Signaling Differentially Alter the Hepatic Metabolome in Mice with Nonalcoholic Steatohepatitis. | 2020 | Details |
| A05463 | 33248441 | J Clin Endocrinol Metab | Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. | 2021 | Details |
| A05474 | 33246008 | Metabolism | Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. | 2020 | Details |
| A05475 | 33244884 | J Cachexia Sarcopenia Muscle | Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. | 2020 | Details |
| A05476 | 33244871 | J Diabetes Investig | Decreased plasma n6 : n3 polyunsaturated fatty acids ratio interacting with high C-peptide promotes non-alcoholic fatty liver disease in type 2 diabetes patients. | 2020 | Details |
| A05482 | 33239899 | Diabetes Metab Syndr Obes | CHDH-PNPLA3 Gene-Gene Interactions Predict Insulin Resistance in Children with Obesity. | 2020 | Details |
| A05510 | 33222696 | Lipids Health Dis | Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in Chinese children and adolescents: a large single-center cross-sectional study. | 2020 | Details |
| A05514 | 33220492 | Mol Metab | Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. | 2020 | Details |
| A05517 | 33220422 | Pharmacol Res | Ugonin J improves metabolic disorder and ameliorates nonalcoholic fatty liver disease by regulating the AMPK/AKT signaling pathway. | 2020 | Details |
| A05522 | 33219985 | Indian J Gastroenterol | Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. | 2020 | Details |
| A05524 | 33219119 | BMJ Open Diabetes Res Care | Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans. | 2020 | Details |
| A05525 | 33218405 | Taiwan J Obstet Gynecol | Elevated serum levels of galectin-3 binding protein are associated with insulin resistance in non-diabetic women after menopause. | 2020 | Details |
| A05532 | 33217052 | J Gastroenterol Hepatol | A review of non-alcoholic fatty liver disease in non-obese and lean individuals. | 2020 | Details |
| A05544 | 33213837 | Biochem Biophys Res Commun | NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. | 2020 | Details |
| A05546 | 33212947 | Nutrients | Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A05558 | 33206859 | Arq Gastroenterol | INSULIN AND INSULIN RECEPTOR GENE POLYMORPHISMS AND SUSCEPTIBILITY TO NONALCOHOLIC FATTY LIVER DISEASE. | 2020 | Details |
| A05559 | 33205999 | Am J Physiol Gastrointest Liver Physiol | GPCRs get fatty: the role of G protein-coupled receptor signaling in the development and progression of nonalcoholic fatty liver disease. | 2020 | Details |
| A05566 | 33204675 | Can J Gastroenterol Hepatol | Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand? | 2020 | Details |
| A05579 | 33201570 | J Gastroenterol Hepatol | The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development. | 2020 | Details |
| A05583 | 33200011 | World J Hepatol | Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know! | 2020 | Details |
| A05584 | 33199780 | Nat Commun | AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. | 2020 | Details |
| A05594 | 33195636 | World J Clin Cases | Relationship between non-alcoholic fatty liver disease and coronary heart disease. | 2020 | Details |
| A05600 | 33194172 | Ther Adv Endocrinol Metab | The relation between serum adipose differentiation-related protein and non-alcoholic fatty liver disease in type 2 diabetes mellitus. | 2020 | Details |
| A05603 | 33193105 | Front Endocrinol (Lausanne) | Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH. | 2020 | Details |
| A05611 | 33190008 | Complement Ther Clin Pract | The effects of sumac (Rhus coriaria L.) powder supplementation in patients with non-alcoholic fatty liver disease: A randomized controlled trial. | 2020 | Details |
| A05614 | 33187278 | Nutrients | The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2020 | Details |
| A05617 | 33186794 | Biomed Pharmacother | Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. | 2020 | Details |
| A05621 | 33186123 | Aging (Albany NY) | The nuclear and cytoplasmic roles of miR-320 in non-alcoholic fatty liver disease. | 2020 | Details |
| A05626 | 33184849 | J Cell Physiol | Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis. | 2020 | Details |
| A05646 | 33176658 | Curr Diabetes Rev | Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis. | 2021 | Details |
| A05649 | 33173745 | Adv Sci (Weinh) | The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36. | 2020 | Details |
| A05652 | 33172399 | BMC Nephrol | Elevated alanine aminotransferase and low aspartate aminotransferase/alanine aminotransferase ratio are associated with chronic kidney disease among middle-aged women: a cross-sectional study. | 2020 | Details |
| A05655 | 33171699 | Diagnostics (Basel) | Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. | 2020 | Details |
| A05661 | 33169409 | Hepatology | Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. | 2021 | Details |
| A05662 | 33169375 | Br J Pharmacol | Exploiting oxidized lipids and the lipid-binding GPCRs against cardiometabolic diseases. | 2020 | Details |
| A05668 | 33166032 | Phytother Res | Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: A randomized clinical trial. | 2020 | Details |
| A05669 | 33165444 | Int J Clin Exp Pathol | Higher non-HDL-cholesterol to HDL-cholesterol ratio is linked to increase in non-alcoholic fatty liver disease: secondary analysis based on a longitudinal study. | 2020 | Details |
| A05674 | 33164398 | Zhongguo Zhong Yao Za Zhi | [Mechanism of Alisma orientale in treating nonalcoholic fatty liver disease]. | 2020 | Details |
| A05677 | 33163832 | Hepatol Commun | Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. | 2020 | Details |
| A05678 | 33163831 | Hepatol Commun | Loss of Hepatic Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Links Nonalcoholic Steatohepatitis to Atherosclerosis. | 2020 | Details |
| A05680 | 33162737 | Ann Gastroenterol | Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. | 2020 | Details |
| A05689 | 33157223 | J Ethnopharmacol | Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells. | 2020 | Details |
| A05693 | 33153126 | Nutrients | Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. | 2020 | Details |
| A05694 | 33152949 | Biomed Pharmacother | Prophylactic and therapeutic effects of different doses of vitamin C on high-fat-diet-induced non-alcoholic fatty liver disease in mice. | 2020 | Details |
| A05695 | 33152943 | Biomed Pharmacother | The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. | 2020 | Details |
| A05701 | 33149882 | Ther Adv Endocrinol Metab | Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. | 2020 | Details |
| A05705 | 33148902 | J Med Invest | Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. | 2020 | Details |
| A05715 | 33144092 | Peptides | Chemerin/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway. | 2020 | Details |
| A05720 | 33143628 | Curr Diabetes Rev | Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes. | 2021 | Details |
| A05722 | 33143061 | Nutrients | Cafeteria Diet and High-Fructose Rodent Models of NAFLD Differ in the Metabolism of Important PUFA and Palmitoleic Acid without Additional Influence of Sex. | 2020 | Details |
| A05723 | 33143043 | Biomolecules | Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update. | 2020 | Details |
| A05735 | 33139661 | Int J Mol Sci | Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. | 2020 | Details |
| A05736 | 33139607 | Nutrients | Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? | 2020 | Details |
| A05744 | 33134908 | JHEP Rep | Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor. | 2020 | Details |
| A05747 | 33134485 | Transplant Direct | Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. | 2020 | Details |
| A05749 | 33133304 | Dis Markers | Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. | 2020 | Details |
| A05752 | 33132636 | World J Gastroenterol | Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis? | 2020 | Details |
| A05753 | 33132631 | World J Gastroenterol | Role of betaine in liver disease-worth revisiting or has the die been cast? | 2020 | Details |
| A05758 | 33131199 | J Diabetes Investig | Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. | 2020 | Details |
| A05767 | 33126575 | Nutrients | Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. | 2020 | Details |
| A05769 | 33126411 | Cells | The Role of PPARs in Disease. | 2020 | Details |
| A05775 | 33125080 | J Clin Endocrinol Metab | Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A05776 | 33123227 | Exp Ther Med | Interactions between leptin and insulin resistance in patients with prediabetes, with and without NAFLD. | 2020 | Details |
| A05779 | 33122078 | Gene | TCTP participates in hepatic metabolism by regulating gene expression involved in insulin resistance. | 2020 | Details |
| A05780 | 33121337 | Cell Cycle | Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS/TLR4 signaling pathway. | 2020 | Details |
| A05791 | 33116702 | Diabetes Metab Syndr Obes | Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A05804 | 33113993 | Nutrients | Effects of a Low Dose of Caffeine Alone or as Part of a Green Coffee Extract, in a Rat Dietary Model of Lean Non-Alcoholic Fatty Liver Disease without Inflammation. | 2020 | Details |
| A05807 | 33113501 | Phytomedicine | Modulation of IR as a therapeutic target to prevent NASH using NRF from Diceratella elliptica (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor. | 2020 | Details |
| A05808 | 33112796 | J Endocrinol | GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner. | 2021 | Details |
| A05810 | 33110211 | Exp Mol Med | The impact of endotrophin on the progression of chronic liver disease. | 2020 | Details |